Caspian Oliai - Concepedia

Author

Caspian Oliai

University of California, Los Angeles ORCID

Also Known As

C. Oliai, CASPIAN OLIAI, Caspian H Oliai, Caspian H. Oliai, Caspian Oliai

764

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

University of California, Los Angeles Drexel University Stanford University University of California, Davis University of Utah

About

Caspian Oliai is an author at University of California, Los Angeles specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	6	6	233
2	Immunology	4	4	123
3	Health Sciences	1	1	30
4	Cell Biology	1	1	72
5	Clinical Immunology	1	1	10

Caspian Oliai

Publications

581

Citations

H-Index

Page 1

	Year	Citations
CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Sarah M. Larson, Christopher M. Walthers, Brenda Ji, Cancer Discovery	2022	87
Hyperbaric Oxygen Therapy for Radiation-Induced Cystitis and Proctitis Caspian Oliai, Brandon J. Fisher, A. Jani, International Journal of Radiation OncologyBiologyPhysics Radiation MedicineRadiation TherapyOxygen TherapySurgeryHyperbaric Oxygen Therapy	2012	84
Stereotactic body radiation therapy for the primary treatment of localized prostate cancer Caspian Oliai, Rachelle Lanciano, Brian Sprandio, Journal of Radiation Oncology	2012	74
Dendritic Cells and CD28 Costimulation Are Required To Sustain Virus-Specific CD8+ T Cell Responses during the Effector Phase In Vivo Douglas V. Dolfi, Priyanka Duttagupta, Alina C. Boesteanu, The Journal of Immunology Effector PhaseAdaptive Immune SystemImmunologyImmunologic MechanismCd4 T Cell Responses	2011	72
Allogeneic CD33-directed CAR-NKT cells for the treatment of bone marrow-resident myeloid malignancies Yan-Ruide Li, Ying Fang, Yichen Zhu, Nature Communications	2025	33
Efficacy of checkpoint inhibition after CAR-T failure in aggressive B-cell lymphomas: outcomes from 15 US institutions Ajay Major, Jovian Yu, Navika Shukla, Blood Advances Checkpoint InhibitionImmunologyPathologyCheckpoint InhibitorImmunotherapy	2023	30
SBRT for the Primary Treatment of Localized Prostate Cancer: The Effect of Gleason Score, Dose and Heterogeneity of Intermediate Risk on Outcome Utilizing 2.2014 NCCN Risk Stratification Guidelines Matthew Bernetich, Caspian Oliai, Rachelle Lanciano, Frontiers in Oncology	2014	29
Clinical features of pseudocirrhosis in metastatic breast cancer Caspian Oliai, Michael Douek, Caelainn Rhoane, Breast Cancer Research and Treatment Metastatic Breast CancerBreast OncologyMedicineHistopathologyPathology	2019	26
Outcomes After Brexucabtagene Autoleucel Administered as a Standard Therapy for Adults With Relapsed/Refractory B-Cell ALL Gregory W. Roloff, Ibrahim Aldoss, Noam E. Kopmar, Journal of Clinical Oncology	2024	23
Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity Caspian Oliai, Rasmus T. Hoeg, Anna Pavlova, Blood	2022	17

Page 1